RxDoctor Payments Data

Paula Taylor, NP

Psychiatric/Mental Health · Manalapan, NJNPI 1265086821

Payments from drug & device makers

$717in general payments, 2019–2025

Across 27 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$389
  • AbbVie$113
  • Alkermes, Inc.$69
  • Johnson & Johnson$37
  • Lundbeck LLC$31
  • E.r. Squibb & Sons, L.L.C.$18
  • plus $60 from 4 others

What the payments were for

  • Food & beverage$67093%
  • Education$477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$717 in reported general payments places this provider in the 60th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$58,981
Medicare patients
132
Services billed
648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate30$74,416
VraylarCariprazine Hcl49$71,400
Lurasidone Hcl33$17,438
Aripiprazole74$4,648
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl32$3,620
Quetiapine Fumarate190$3,508
Atomoxetine Hcl38$3,456
Ziprasidone Hcl42$3,268
Fluphenazine Hcl28$3,078
Paliperidone ErPaliperidone12$2,888
Divalproex Sodium ErDivalproex Sodium49$2,833
Bupropion XlBupropion Hcl138$2,282
Alprazolam288$2,089
Clozapine29$1,865
Fluoxetine Hcl138$1,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$37$74,41630 claims
AbbVieVraylar$113$71,40049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Manalapan

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →